64892--5/30/2007--MENTOR_CORP_/MN/

related topics
{property, intellectual, protect}
{regulation, change, law}
{product, liability, claim}
{product, market, service}
{acquisition, growth, future}
{cost, regulation, environmental}
{regulation, government, change}
{system, service, information}
{customer, product, revenue}
{personnel, key, retain}
{condition, economic, financial}
{loss, insurance, financial}
{operation, international, foreign}
Significant product liability claims or product recalls may force us to pay substantial damage awards and other expenses that could exceed our accruals and insurance coverages. We are subject to substantial government regulation, which could have a material adverse effect on our business. If we are unable to continue to develop and commercialize new technologies and products, we may experience a decrease in demand for our products, or our products could become obsolete. If we are unable to compete effectively with existing or new competitors, we could experience price reductions, reduced demand for our products, reduced margins and loss of market share, and our business, results of operations, and financial condition would be adversely affected. If we suffer negative publicity concerning the safety of our products, our sales may be harmed and we may be forced to withdraw products. If changes in the economy and consumer spending reduce consumer demand for our products, our sales and profitability could suffer. If we are unable to implement new information technology systems or upgrade existing systems, our ability to manufacture and sell products, maintain regulatory compliance, and manage and report our business activities may be impaired, delayed, or diminished, which would cause substantial business interruption and loss of sales, customers, and profits. If we are unable to acquire companies, businesses or technologies as part of our growth strategy or to successfully integrate past acquisitions, our growth, sales, and profitability could suffer. We agreed to indemnify Coloplast against specified losses in connection with Coloplast s purchase of our Urology Business, and any demands for indemnification may result in expenses we do not anticipate and distract the attention of our management from our continuing businesses. We may not realize some of the benefits of the Coloplast transaction. We depend upon our key personnel and our ability to attract, train, and retain employees. State legislatures and taxing authorities may create new laws or change their interpretation of existing state and local tax laws that may affect future product demand or create unforeseen tax liabilities. If our intellectual property rights do not adequately protect our products or technologies, others could compete against us more directly, which would hurt our profitability. If third parties claim we are infringing their intellectual property rights, we could suffer significant litigation, indemnification, or licensing expenses or be prevented from marketing our products. We depend on the continued use of our manufacturing plants and on single and sole source suppliers for certain raw materials and licensed or manufactured products, and the loss of, or disruption to, any plant or supplier could adversely affect our ability to manufacture or sell many of our products. Our international business exposes us to a number of risks. Health care reimbursement or reform legislation could materially affect our business. If our use of hazardous materials results in contamination or injury, we could suffer significant financial loss. Future changes in financial accounting standards may cause adverse unexpected revenue or expense fluctuations and affect our reported results of operations. Hedging transactions and other transactions may affect the value of the notes.

Full 10-K form ▸

related documents
64892--5/30/2008--MENTOR_CORP_/MN/
804328--11/5/2009--QUALCOMM_INC/DE
1084876--3/16/2007--RAE_SYSTEMS_INC
50863--2/20/2008--INTEL_CORP
1084876--3/17/2008--RAE_SYSTEMS_INC
1011570--2/29/2008--KNOLL_INC
878828--3/31/2009--WIRELESS_TELECOM_GROUP_INC
880432--9/26/2008--MISONIX_INC
880432--9/28/2009--MISONIX_INC
801898--12/19/2008--JOY_GLOBAL_INC
804328--11/8/2007--QUALCOMM_INC/DE
1011570--3/2/2009--KNOLL_INC
1005010--2/29/2008--ARTHROCARE_CORP
50863--2/26/2007--INTEL_CORP
880432--9/28/2010--MISONIX_INC
945828--9/13/2006--AMERITYRE_CORP
1099800--2/26/2010--Edwards_Lifesciences_Corp
739944--3/10/2009--MEDTOX_SCIENTIFIC_INC
880432--9/28/2007--MISONIX_INC
827099--3/31/2009--TETRIDYN_SOLUTIONS_INC
1099800--3/2/2009--Edwards_Lifesciences_Corp
721371--8/24/2007--CARDINAL_HEALTH_INC
1063254--3/5/2009--S1_CORP_/DE/
797448--3/31/2006--VERSO_TECHNOLOGIES_INC
739944--3/11/2008--MEDTOX_SCIENTIFIC_INC
109831--3/22/2006--INAMED_CORP
801898--12/21/2007--JOY_GLOBAL_INC
76334--8/28/2008--PARKER_HANNIFIN_CORP
912093--8/31/2010--JDS_UNIPHASE_CORP_/CA/
1011582--9/12/2006--DIGENE_CORP